Product pipeline
Cohesive, forward-looking product pipeline layout
Cohesive, forward-looking product pipeline layout
See More
Recruit
分类筛选
条件：
清空条件
Currently Enrolling
Phase I multiple-center, open-label, dose escalation and dose expansion study for assessing the safety, tolerability, pharmacokinetics and anti-tumor effect of PLB1004 in treatment of advanced non-small cell lung cancer
Indication：
Cancer species：non-small cell lung cancer
Time：2022-09-26
Currently Enrolling
A multi-center, multi-queue, open Phase II clinical trial to evaluate the effectiveness and safety of Vebreltinib enteric capsules on late-stage non-small cell lung cancer with c-Met irregularity.
Indication：Treatment of adults with locally advanced or metastatic non-small cell lung cancer with interstitial epithelial transforming factor (MET) exon 14 jump
1. Execution of letter of informed consent;
2. Male or female of age 18 and above;
Cancer species：non-small cell lung cancer
Time：2022-09-26
Business development
Avistone is dedicated to autonomous research of anti-tumor drugs
Avistone is dedicated to autonomous research of anti-tumor drugs, offering innovative therapy to cancer patients around the world. We possess a mature drug discovery, clinical development and commercialization platform. We are happy to work with biotechnology and pharmaceutical companies worldwide at any stage of research and development. Commercialization of scientific achievements is typically through external licensing and introduction of products.
Company Profile
©2022 Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd.
京ICP备2020040683号-2